Form 4: Dianthus Therapeutics, Inc. /DE/ Executive Sells Shares
Insider Transaction (Form 4)
Adam M Veness, SVP, General Counsel and Sec. of Dianthus Therapeutics, Inc. /DE/, sold 20,000 shares of common stock on August 7, 2026.
Summary
- Option exercise/conversion: acquired 3,833 Common Stock at $17.88 ($68,534) on August 7, 2026; holds 3,833 after (Direct).
- Open-market sale: disposed of 3,217 Common Stock at $110.61 ($355,832) on August 7, 2026; holds 616 after (Direct).
- Open-market sale: disposed of 616 Common Stock at $111.18 ($68,487) on August 7, 2026 (Direct).
- Option exercise/conversion: acquired 16,167 Common Stock at $17.88 ($289,066) on August 10, 2026; holds 16,167 after (Direct).
- Open-market sale: disposed of 16,167 Common Stock at $110.38 ($1,784,513) on August 10, 2026 (Direct).
- Option exercise/conversion: disposed of 3,833 Stock Option (Right to Buy) on August 7, 2026; holds 76,167 after (Direct).
- Option exercise/conversion: disposed of 16,167 Stock Option (Right to Buy) on August 10, 2026; holds 60,000 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,208,833 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Adam M Veness — Officer (SVP, General Counsel and Sec.)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-07 | Option exercise/conversion | Common Stock | 3,833 | $18 | $68.5K | 3,833 |
| 2026-08-07 | Open-market sale | Common Stock | 3,217 | $111 | $355.8K | 616 |
| 2026-08-07 | Open-market sale | Common Stock | 616 | $111 | $68.5K | 0 |
| 2026-08-10 | Option exercise/conversion | Common Stock | 16,167 | $18 | $289.1K | 16,167 |
| 2026-08-10 | Open-market sale | Common Stock | 16,167 | $110 | $1.8M | 0 |
| 2026-08-07 | Option exercise/conversion | Stock Option (Right to Buy) | 3,833 | — | — | 76,167 |
| 2026-08-10 | Option exercise/conversion | Stock Option (Right to Buy) | 16,167 | — | — | 60,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-07 | Option exercise/conversion (3,833 shares) |
| 2026-08-07 | Open-market sale (3,217 shares) |
| 2026-08-07 | Open-market sale (616 shares) |
| 2026-08-10 | Option exercise/conversion (16,167 shares) |
| 2026-08-10 | Open-market sale (16,167 shares) |
| 2026-08-07 | Option exercise/conversion (3,833 shares) |
| 2026-08-10 | Option exercise/conversion (16,167 shares) |
Keywords
insider transaction, Form 4, DNTH, Dianthus Therapeutics, Inc. /DE/, bearish, Adam M Veness
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.